🇮🇩

Indonesia for Biotech / Life Sciences

asiaWorldwideBIOTECH / LIFE SCIENCES
61
Overall
53
BIOTECH
Industry Rank
#20of 27
Key Strength
Visa
Tax Regime
Worldwide
Verdict
Best For

Founders seeking capital - Indonesia's funding access (80/100) suits startups that need VC relationships and government co-investment programs.

Not Ideal For

Founders whose top priority is minimising corporate tax - Indonesia's corporate tax score (37/100) is not a standout advantage.

Bottom Line

Ranked #20 of 27 jurisdictions for Biotech / Life Sciences. Indonesia's Biotech / Life Sciences score of 53/100 is close to its overall score of 61/100, indicating balanced performance across dimensions.

BIOTECH / LIFE SCIENCES-WEIGHTED DIMENSION PROFILE

Muted: default profile / Blue: industry-weighted

Strengths
Visa90

Strong visa environment for biotech / life sciences operators.

Funding80

Strong funding environment for biotech / life sciences operators.

Family75

Strong family environment for biotech / life sciences operators.

Watch Outs
Tax37

Lower tax score - verify current requirements carefully.

Residency43

Lower residency score - verify current requirements carefully.

Practical45

Lower practical score - verify current requirements carefully.

Key Metrics for Biotech / Life Sciences
22%
Corporate Tax
30
Active VCs
$1.2B
VC Deployed
Yes
Gov Grants
No
EU Funding
50
Talent Pool
No
IP Box Regime
30
Incorporation

Why Indonesia Works for Biotech / Life Sciences

Funding access (80/100) is a standout for Indonesia Biotech / Life Sciences companies. The local market has 30 active VC funds, with average seed checks of $500K. Government grant programs include Merah Putih Fund and LPDP Startup ($70K). Non-dilutive capital availability reduces the pressure to give up equity at early stage, which is particularly valuable for capital-efficient Biotech / Life Sciences businesses.

Family viability (75/100) is a genuine strength for Indonesia - important for Biotech / Life Sciences founders relocating with a partner or children. The cost of living index is 32 (NYC = 100), with a comfortable family monthly budget of $2K. Safety scores 55/100. International schools are available, and healthcare quality scores 55/100 with private insurance running approximately $180/month.

Startup ecosystem quality (70/100) is a key reason Indonesia ranks well for Biotech / Life Sciences. 8 unicorns have originated here, signalling institutional knowledge about building and scaling companies. Talent pool quality scores 50/100, and average senior developer salaries run $18K/year. Sector specializations relevant to Biotech / Life Sciences include: ride-hailing, e-commerce, fintech.

Watch Outs for Biotech / Life Sciences Founders in Indonesia

Corporate tax (37/100): Tax efficiency is not the primary reason to choose Indonesia for Biotech / Life Sciences operations. Founders whose primary goal is minimising the corporate tax line should model effective rates carefully and compare against jurisdictions with zero or near-zero corporate tax.

Residency access (43/100): Visa and residency options for non-citizens are more limited or complex than in purpose-built founder-friendly jurisdictions. Founders who need a fast, reliable residency pathway should verify program eligibility requirements before choosing Indonesia as a base.

Operational friction (45/100): Banking for foreign founders is difficult, which is one of the most common pain points reported by early-stage companies operating here. A local director is required, adding ongoing governance cost. Foreign ownership restrictions mean a local partner or nominee arrangement may be necessary. Budget for setup costs and additional legal fees when modelling the total cost of incorporating here.

Setup Requirements for Biotech / Life Sciences in Indonesia
  1. Entity type: Local director or partner arrangement required for foreign-owned entities
  2. Banking: difficult access for foreign founders. Common options include BCA, Mandiri, BNI.
  3. Formation: approximately 30 days to incorporate, estimated cost $2K plus annual compliance of $3K
  4. Licensing: Regulator - BPOM (Indonesian FDA)
  5. Timeline: Estimated 60-120 days from decision to fully operational (company + banking + residency)
  6. Visa pathway: B211A Digital Nomad Visa (minimum income $2K/month, 6-month initial permit)
Industry Key Facts
BPOM (Indonesian FDA)
Regulator
Developing - cost-effective
Clinical Trials
Weak - significant risk
Patent Enforcement
Restricted in pharma
Foreign Ownership
Compare Indonesia vs Top Alternatives for Biotech / Life Sciences
🇮🇩Indonesia
53
🇹🇭Thailand
50

Biotech / Life Sciences industry scores

🇮🇩Indonesia
53
🇸🇬Singapore
73

Biotech / Life Sciences industry scores

Top Biotech / Life Sciences Jurisdictions
Frequently Asked Questions
Is Indonesia good for Biotech / Life Sciences in 2026?

Indonesia ranks #20 of 27 jurisdictions for Biotech / Life Sciences on NomadSignal's scoring model, with an industry-weighted score of 53/100. The top strengths for Biotech / Life Sciences founders are funding access and family viability. Whether it is the right choice depends on your funding stage, personal tax situation, and whether you are relocating alone or with a family.

What is the corporate tax rate in Indonesia?

Indonesia applies a statutory corporate tax rate of 22%. The jurisdiction has 71 active tax treaties. For Biotech / Life Sciences founders, corporate tax efficiency carries a 8% weight in the industry scoring model. Verify the current effective rate with a local advisor before making an incorporation decision.

Does Indonesia have Biotech / Life Sciences-specific programs or incentives?

BPOM (Indonesian FDA equivalent) is the regulatory body. Clinical trial infrastructure exists but is developing. Patent enforcement is weak. The large population provides significant clinical trial recruitment potential. Foreign-owned pharmaceutical companies face ownership restrictions. NomadSignal evaluates Biotech / Life Sciences-specific factors including Regulatory Approval Pathway, Clinical Trial Environment, Patent Regime for Biologics as part of the industry score. Check the country's official government and innovation agency websites for current program details.

How does Indonesia compare to other jurisdictions for Biotech / Life Sciences?

Indonesia ranks #20 for Biotech / Life Sciences with 53/100. The #1 ranked jurisdiction is Singapore at 73/100. The gap is driven mainly by corporate tax, where Indonesia is weaker. Use NomadSignal's comparison pages to evaluate Indonesia head-to-head against specific alternatives.

Discussion (0)

A community of sovereign individuals - founders, families, and remote operators. Share what you know, ask what you don't.

No comments yet - be the first to share what you know about this page.

Data as of March 2026. Not legal, tax, or immigration advice.